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Abstract
Background: Recent clinical trials reported conflicting results on the reduction of new-onset diabetes using RAS
blocking agents. Therefore the role of these agents in preventing diabetes is still not well defined. Ramipril is an
ACE inhibitor (ACEi), that has been shown to reduce cardiovascular events in high risk patients and post-hoc
analyses of the HOPE trial have provided evidence for its beneficial action in the prevention of diabetes.
Methods:  The ADaPT investigation ("ACE inhibitor-based versus diuretic-based antihypertensive primary
treatment in patients with pre-diabetes") is a 4-year open, prospective, parallel group phase IV study. It compares
an antihypertensive treatment regimen based on ramipril versus a treatment based on diuretics or betablockers.
The primary evaluation criterion is the first manifestation of type 2 diabetes. The study is conducted in primary
care to allow the broadest possible application of its results. The present article provides an outline of the
rationale, the design and baseline characteristics of AdaPT and compares these to previous studies including
ASCOT-BLPA, VALUE and DREAM.
Results: Until March 2006 a total of 2,015 patients in 150 general practices (general physicians and internists)
throughout Germany were enrolled. The average age of patients enrolled was 67.1 ± 10.3 years, with 47% being
male and a BMI of 29.9 ± 5.0 kg/m2. Dyslipidemia was present in 56.5%. 37.8% reported a family history of diabetes,
57.8% were previously diagnosed with hypertension (usually long standing). The HbA1c value at baseline was 5.6
%. Compared to the DREAM study patients were older, had more frequently hypertension and patients with
cardiovascular disease were not excluded.
Conclusion: Comparing the ADaPT design and baseline data to previous randomized controlled trial it can be
acknowledged that AdaPT included patients with a high risk for diabetes development. Results are expected to
be available in 2010. Data will be highly valuable for clinical practice due to the observational study design.
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Background
Hypertension is the leading cause of morbidity and mor-
tality worldwide [1]. The concomitant manifestation of
type 2 diabetes mellitus leads to a substantial further
increase in risk [2,3]. While about 50% of patients in Ger-
man primary care were hypertensive in a recent cross-sec-
tional survey, 12% of all patients had a co-manifestation
of hypertension and diabetes [4].
Not only hypertensive patients with diabetes, but also
hypertensive patients without diabetes tend to be resistant
to insulin stimulated glucose uptake and are hyperinsuli-
naemic compared with normotensive controls [5]. About
20% of patients with hypertension will develop type 2
diabetes in a three year period [6] and new onset diabetes
in treated hypertensive patients is not trivial as recent
studies suggest [7,8].
The risk for subsequent cardiovascular (CV) disease in
patients with pre-diabetes is not different from those who
had both hypertension and diabetes already at baseline
[9]. The adjusted relative risk of events was about 3-times
higher in both previous and new onset diabetes compared
to patients with hypertension but without diabetes [9].
Antihypertensive drugs and new-onset diabetes
The roles of antihypertensive agents and in particular
those that inhibit the RAS in the acceleration or decelera-
tion of diabetes manifestation have been discussed con-
troversial and study results on this question are not
consistent.
The RAS itself plays a pivotal role in the development of
diabetes. Over-activity appears to be linked to reduced
insulin and glucose delivery to the peripheral skeletal
muscle and impaired glucose transport and response to
insulin signalling pathways, thus increasing insulin resist-
ance [10]. Activation of a local pancreatic RAS, in particu-
lar within the islets, may represent an independent
mechanism for the progression of islet cell damage in dia-
betes. In fact, impaired pancreatic islet function may pre-
dominate quantitatively over peripheral insulin resistance
in impaired glucose tolerance [11].
Drugs that interrupt the RAS like angiotensin converting
enzyme inhibitors (ACEi) and angiotensin receptors
blockers (ARBs) are likely to be beneficial in the preven-
tion of diabetes [10,12]. A series of recent large-scale pro-
spective randomised studies of 3–6 year duration such as
CAPP, INSIGHT, LIFE or ALLHAT, reported a remarkably
consistent reduction in the incidence of type 2 diabetes in
hypertensive patients reported with either ACEi-based or
ARB-based therapy (reviewed by Jandeleit-Dahm in [10]).
The comparator groups were based on thiazide-diuretics,
β-blockers, the calcium channel blocker amlodipine or
placebo, respectively.
In a large meta-analyis, Abuissa et al. calculated the aver-
age risk reduction in 6 of these trials using ACEi and 7 tri-
als using ARBs. The reduction of new onset-diabetes was
24% for ACEi, 23% for ARBs and 23% for the combined
data-set [13]. Furthermore a recent network meta-analysis
of randomized controlled trials showed that while
patients taking betablockers and diuretics show an
increased incidence of diabetes, it is reduced in patients
using ACEi or ARBs (Figure 1) [14,15].
Endpoint studies to elucidate the role of antihypertensive
agents on new onset diabetes related morbidity and mor-
tality are however scarce. The VALUE trial with valsartan
was the only trial to include new-onset diabetes as a pre-
specified endpoint [16]. Patients were normoglycemic,
those with abnormal glucose values were excluded. While
16.4% of patients in the amlodipine arm (up to 10 mg)
developed diabetes over a mean follow-up of 4.2 years,
13.1% developed such in the valsartan arm (up to 160
mg); p < 0.0001. The ASCOT-BPLA study, which was a
randomised controlled trial of the prevention of CHD and
other vascular events by BP and cholesterol lowering in a
factorial study design, was prematurely stopped in
December 2004 [17,18]. The study was designed to
resolve whether newer antihypertensive strategies that use
calcium channel blockers (CCBs) and ACEi are superior to
older treatments using betablockers and diuretics. As a key
finding there was a substantial excess of new diabetes
(increase of 30%) in the beta blocker/diuretic arm [17].
DREAM investigated the effect of ramipril (up to 15 mg)
Diabetes incidence – results of full Bayesian network meta- analysis of 22 trials with 143153 patients [14], modified from  [15] Figure 1
Diabetes incidence – results of full Bayesian network meta-
analysis of 22 trials with 143153 patients [14], modified from 
[15].
Treatment
ARBs
ACEi
CCBs
Betablocker
Diuretic
Odds ratio (95% CI)   
Placebo
0.50              0.80    1.00   1.25               2.00
Odds Ratio for new-onset Diabetes
0.822 (0.679-0.999)
0.889 (0.765-1.036)
1.051 (0.893-1.263)
1.250 (1.055-1.503)
1.347 (1.133-1.632)
Reference
Figure 1Cardiovascular Diabetology 2008, 7:22 http://www.cardiab.com/content/7/1/22
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compared to placebo [6]. In this randomised controlled
trial ramipril significantly increased regression to normo-
glycemia in patients with impaired glucose tolerance. It
did however not influence the risk of a combined end-
point consisting of new-onset diabetes or death over a 3
year observational period. Interpretation of DREAM is
limited by a number of details: 1) hypertension was not
an inclusion criterion (mean blood pressure at baseline
136/83 mmHg), 2) comparison was made to placebo
instead of diuretics or betablockers (which would be rea-
sonable based on the analysis of Elliott [15]) and 3) beta-
blockers were allowed in both the ramipril and placebo
groups.
Rationale for ADaPT
Thus, despite the strong evidence for a reduction of new-
onset diabetes from several RCTs and meta-analyses, there
is an ongoing controversy about the clinical significance,
the comparability of agents within one drug class, or the
generalisability of these findings into clinical practice [19-
21]. The "ACE inhibitor-based versus diuretic-based antihyper-
tensive primary treatment in patients with prediabetes"
(ADaPT) study addresses this issue. On the basis of the
existing body of evidence, it appeared likely that patients
with impaired fasting glucose (IGF) according to the
screening on pre-diabetes (PreDiSc Score) will benefit
from tight blood pressure control and further effects from
RAS-inhibition by the ACEi ramipril in terms of manifes-
tation of type 2 diabetes. The long-term outcomes of this
treatment regimen will be compared to a regimen based
on diuretics and/or β-blockers.
Materials and methods
Design
The ADaPT investigation is a comparative Post Marketing
Surveillance according to §67(6) German Drug Law, per-
formed by the German Hypertension League. It was
designed as an open, prospective, non-randomised paral-
lel group observational investigation in 150 general prac-
tices (general physicians and internists) throughout
Germany.
Patient population
Inclusion criteria
Patients eligible for this study were at high risk for the
development of type 2 diabetes according to the modified
PreDiSc  Score [22]: They had to be ≥ 45 year old
(amended, original protocol ≥ 55 years), have hyperten-
sion (systolic blood pressure ≥ 140 and/or diastolic blood
pressure  ≥ 90 mmHg), impaired fasting glucose (IFG)
defined as glucose level 110–125 mg/dl in venous plasma
or 100–109 mg/dl in capillary whole blood, and a glyco-
sylated haemoglobin A1c (HbA1c) of 6–6.5% determined
within the last six months.
Exclusion criteria
Patients were excluded if they received any antidiabetic
drug treatment, had overt type 2 diabetes, fasting blood
glucose level ≥ 126 mg/dl in venous plasma or ≥ 110 mg/
dl in capillary blood, or casual plasma glucose concentra-
tions ≥ 200 mg/dl, congestive heart failure, chronic renal
insufficiency, history of myocardial infarction, stroke,
drug or alcohol abuse, or contraindications against one of
the drugs applied.
Definitions
For definitions of normal glucose tolerance (NGT),
impaired fasting glucose (IFG), impaired glucose toler-
ance (IGT) and overt diabetes (DM) see Table 1. PreDiSc
Score: The score indicates the presence of pre-diabetes
with a diagnostic sensivity of 78% and a specificity of 37%
using the following parameters: blood pressure (BP) ≥
140/90 mmHg, capillary fasting blood glucose ≥ 100 mg/
dl (STIX) and age ≥ 55 years. Sensivity can be increased to
79% and specificity to 74% by additional determination
of the HbA1c value (≥ 6%) [22].
Antihypertensive treatment
Patients in Group 1 receive Ramipril either as mono-
therapy (Delix®, Sanofi-Aventis, Berlin) or in combination
with Felodipin (Delmuno®, Sanofi-Aventis, Berlin),
patients in Group 2 received any other diuretic-based or
β-blocker-based therapy without using ACEi or ARBs.
Ramipril was chosen as the antihypertensive drug in one
group, as long-standing experience from several clinical
Table 1: Values of plasma glucose (venous blood) for the diagnosis of diabetes mellitus* and other categories of hyperglycemia 
according to DDG criteria [30]
mg/dl mmol/l
Fasting 2 h OGTT Fasting 2 h OGTT
NGT Normal glucose tolerance < 100 < 140 < 5.6 < 7.8
IFG Impaired fasting glucose 100–125 - 5.6–6.9 -
IGT Impaired glucose tolerance < 126 and 140–199 < 7.0 and 7.8–11.0
DM Diabetes mellitus ≥ 126 and/or ≥ 200 ≥ 7.0 and/or ≥ 11.1
IGT classification according to 2 h OGG is only appropriate if the NGT value is below the threshold value for diabetes mellitus.Cardiovascular Diabetology 2008, 7:22 http://www.cardiab.com/content/7/1/22
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studies including large endpoint studies have accumu-
lated with this agent [23-25]. The Heart Outcomes Preven-
tion Evaluation (HOPE) Study showed that ramipril is
effective in preventing major cardiovascular events in
high-risk patients without hypertension or those whose
hypertension was sufficiently controlled with other treat-
ments [26].
Generally, treatment regimens in this study can be chosen
in accordance with the recommendations of the German
Hypertension League and the European Society of Hyper-
tension [27,28] For initial treatment monotherapy or a
low-dose combination regimen is suggested. If the
response is inadequate, possible options include increas-
ing the dose, changing the drug or introduction of further
combination drugs [29]. All drugs are administered
within the approved labelling.
Advice about the investigation has been obtained by the
institutional review board of the Charité Berlin, Germany
– Campus Benjamin-Franklin. Written informed consent
was obtained from every patient in writing. The planned
follow-up period is four years.
Endpoints
The primary evaluation criterion of this observational
study is the first manifestation of type 2 diabetes accord-
ing to the current guidelines of the German Diabetes Soci-
ety (see table 1). [30] Further evaluation criteria are the
deterioration of pre-diabetes indicated by an increase of
HbA1c of at least 10% compared to baseline value within
4 years, the initiation of antidiabetic glucose lowering
medication, an increase of fasting glucose levels, change
of HbA1c compared to baseline, BP reduction, achieve-
ment of the target BP <130/80 mmHg after 12 months
and at the 4 year follow-up, time needed to reach target
BP, major cardiovascular (CV) events (first manifestation
of symptomatic coronary heart disease (CHD) and/or
peripheral arterial occlusive disease and/or cerebrovascu-
lar events), type and frequency of Adverse Events (AE) or
Serious Adverse Events (SAE), and total mortality. In the
diuretic-based therapy group, time to switch to ACE-based
or ARB-based therapy will also be analysed.
Investigational plan
Table 2 summarizes the investigational plan. Patients are
seen at 7 scheduled visits. Vital signs (BP, heart rate) will
be complemented by height and weight measurements
(determinations of body mass index) and waist and hip
circumference measurement at after 3, 6 and 12 months
and thereafter at yearly intervals. Further, lab examina-
tions of glucose, lipids, inflammatory (high sensitive C-
reactive protein) and renal parameters (with cystatin C to
assess renal function [30,31]) will be done in the same
intervals. Ambulatory BP monitoring is facultative and
will be performed in a subset of patients. AEs will be
recorded and their severity, course and relation to the
medication assessed by the treating physician. Prior as
well as concomitant diseases and concomitant medica-
tion will also be assessed.
Statistical Assumptions and sample size calculation
Sample size calculation for the primary endpoint was
made under the assumption – based on the results of the
ALLHAT study – that during the 4-year observational
period 10.0% of patients in the ramipril-based antihyper-
tensive regimen and 14.3% in the diuretic-based regimen
will develop overt diabetes mellitus [21]. The detectable
risk increase is compatible with 80% power and signifi-
cance of 0.05 is 49% (OR 1,489). Based on this assump-
tion, a sample size of n = 2001 was required. In terms of
randomisation, addressing the literature evidence in
favour of ACE inhibitor treatment, an imbalanced ratio of
2:1 for the number of patients in both treatment groups
was chosen, resulting in a target inclusion number of
1334 patients in group 1 and 667 patients in group 2,
respectively.
Statistical analyses
The following parameters will be analysed: patient demo-
graphics including patient history, capillary und venous
fasting glucose, HbA1c, BP, BMI, waist/hip ratio, concom-
Table 2: ADaPT study plan
Documentation/Investigation Baseline 12 wk 6 mo 1 yr 2 yr 3 yr 4 yr
Clinical examination and medical history x
Information on data protection x
Blood pressure, heart rate x x x x x x x
Physical examination: height, weight, waist and hip circumference x x x x x
Laboratory screening (central laboratory): Blood glucose, HbA1c x x x x x x x
Laboratory values: hsCRP, total cholesterol, LDL-C, HDL-C, TG, cystatin C, potassium, 
albumin, OGTT
x xxxx
ABPM (optional) x xxxx
AE, SAE x x xxxx
Wk = weeks; mo = months; yr = years; hsCRP = high sensitive C-reactive protein; ABPM = ambulatory blood pressure monitoring; AE = Adverse 
Events; SAE = Serious Adverse EventsCardiovascular Diabetology 2008, 7:22 http://www.cardiab.com/content/7/1/22
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itant medications, percentage of patients with prediabetes
according to PreDiSc parameters [22], total cholesterol,
HDL cholesterol, LDL cholesterol, triglycerides, urinary
albumin, and high-sensitive C-reactive protein.
Patients treated with ramipril (and ramipril-based combi-
nation therapy) and patients who received various other
antihypertensive drugs (with the exception of ACEi or
ARBs) will be compared. Statistical analyses of the data
will be performed as exploratory analyses. Descriptive sta-
tistics for continuous target data per treatment group and
per total contain the following: number of patients,
means ± standard deviation, median, minimum and max-
imum. The absolute and relative frequency in percentages
will be determined. Per treatment group 95% confidence
intervals for the means of continuous target data as well as
for the relative frequency of categorical target data will be
calculated using appropriate methods.
For comparison of the treatment groups with respect to
the incidence of specific events (e.g. patients with first
manifestation of diabetes mellitus type 2 or proportion of
patients with deterioration of pre-diabetes), the chi-
square or the log-rank tests will be used to compare the
"survival curves". An interim analysis is scheduled after
the first and second year of the observation. However, the
overall significance levels will not be adjusted.
Baseline Characteristics
Enrolment in AdaPT started in August 2004. The last
patient out of a total of 2,015 patients was included in
March 2006 (table 3). 1,353 patients were enrolled into
the ACEi-based group and 662 patients got a diuretic-
based therapy. While age was similar between both
groups the ACEi-based group had more male patients
(51.4 vs. 42.6%). BMI (29.9 ± 5.0 vs. 29.8 ± 4.8 kg/m2)
and waist-to-hip-ratio (0.95 ± 0.1 vs. 0.93 ± 0.1) were
almost identical in both study groups. Dyslipidemia
(56.5%), hypertension (57.8%) and overweight (43.3%)
and obesity (42.6%) were the frequent baseline character-
istics of patients in both groups. Baseline characteristics of
AdaPT are displayed in table 3 and compared to other
recent studies on the incidence of diabetes being treated
with RAS blocking agents vs. conventional drugs.
Discussion
Although there are several trials with a RAS based pharma-
cotherapy that report a reduction in the development of
diabetes compared to diuretics and betablockers, these
analyses were mostly post-hoc and not predefined. The
only trials with a pre-defined new-onset diabetes end-
point were ASCOT-BPLA [17,18], VALUE [16] and
DREAM [6] (new-onset diabetes as part of the primary
endpoint). While there was a significant reduction of new-
onset diabetes in ASCOT-BLPA (HR 0.70 [95%CI 0.63–
0.78]) and VALUE (HR 0.77 [95%CI 0.69–0.86]) there
was none in DREAM (HR 0.91 [95%CI 0.80–1.03]). Study
duration was 5.5 (median), 4.2 (mean) and 3.0 (median)
years. Within this setting the trial with the longest study
duration had the most pronounced effect on diabetes
development (see table 4).
Inclusion and exclusion criteria were also substantially
different between ASCOT-BPLA, VALUE and DREAM.
ASCOT-BPLA and VALUE included patients with treated
or newly diagnosed hypertension being at least 40 years
(ASCOT-BLPA) or 50 years old (VALUE). Neither
impaired fasting plasma glucose nor glucose tolerance
was an inclusion criterion. DREAM on the other hand
included patients 30 years and above with either impaired
fasting plasma glucose or glucose tolerance. Diagnosis of
hypertension was not required.
What is the additional value of AdaPT ?
The primary goal of AdaPT is to compare the effects of two
antihypertensive combination therapies, an ACE inhibitor
based treatment with a diuretic- (or betablocker)-based
treatment on the incidence of new-onset of type 2 diabe-
tes. To provide adequate power to discriminate a potential
differential effect of these therapies, the trial is being con-
ducted in pre-diabetic patients with hypertension and
metabolic disorders in which there is a high probability
for the development of diabetes.
AdaPT is conducted as an observational study in daily
practice in Germany allowing for the widest possible
applicability of the results obtained. This is important
because there is considerable heterogeneity in patient
management in daily practice and patients with pre-dia-
betes in clinical trials usually differ substantially from
those in clinical trials. Taking the PreDiSc  Score as a
screening algorithm, the study allows physicians to effec-
tively screen for a high risk for the development of diabe-
tes. This would, in case of positive results, serve as an easy
screening tool for high risk patients in the future.
Compared to the previously mentioned trials AdaPT
included patients at a higher risk for the development of
diabetes based on the selection criteria age, presence of
hypertension, an impaired fasting glucose and the missing
exclusion of prior cardiovascular disease. As opposed to
DREAM (Placebo control) AdaPT includes patients
treated with betablockers or diuretics as a control group.
This further enhances the likelihood of a differential effect
based on the previously mentioned data by Abuissa [32],
Elliott [15] and Lam [14] (see also Figure 1). Together
with the 4 year follow-up it appears likely that AdaPT may
document a reduced incidence of diabetes.Cardiovascular Diabetology 2008, 7:22 http://www.cardiab.com/content/7/1/22
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The PreDiSc Score
The fact that a score (PreDiSc) is applied in the ADaPT
investigation to prospectively identify eligible patients
represents a novel approach, since it shifts the conven-
tional focus from individual risk factors (hypertension,
dyslipidaemia) to a more comprehensive view that con-
siders absolute patient risk [3,33]. To our knowledge, such
an approach has only been pursued in retrospective post-
hoc investigations, for example in a current analysis of the
LIFE study [34].
The oral glucose tolerance test (OGTT) is the standard
screening test in high risk populations (identified by med-
ical history), but the fasting plasma glucose test is more
convenient under daily practice conditions. [35] Deter-
mining fasting plasma glucose lacks sensitivity however
and may miss a number of patients with diabetes. Another
possible variable to determine glycaemic control is HbA1c
but is less suitable for a general screening. [36,37]
Against this background, the Pre-Diabetes Score (PreDiSc)
Study established a set of easy-to-determine clinical and/
or laboratory parameters with close correlation to the out-
comes of an OGTT [22]. Indeed, using the HbA1c alone
yielded low sensitivity (58%) as did fasting glucose alone
(62%). However, a combination of age ≥ 55 years, systolic
BP of ≥ 140 mmHg, fasting glucose ≥ 110 – 126 mg/dl,
elevated HbA1c ≥ 6% and abdominal obesity (waist cir-
Table 3: Baseline characteristics of the enrolled patients in AdaPT-study – compared to other trials
VALUE [16] ASCOT-BPLA [17] DREAM [6,38] AdaPT
Valsartan Amlodipine Amlodipine Atenolol Ramipril Placebo ACEi Diuretic
(n = 7649) (n = 7596) (n = 9639) (n = 9618) (n = 2.623) (n = 2.646) (n = 1.353) (n = 662)
Age 
(mean, years)
67.2 ± 8.2 67.3 ± 8.1 63.0 ± 8.5 63.0 ± 8.5 54.7 ± 10.9 54.7 ± 10.9 67.3 ± 10.4 66.5 ± 10.2
Male gender (%) 57.6 57.5 77 77 40.3 41.3 51.4 42.6
BMI (mean, kg/m2) 28.6 ± 5.1 28.7 ± 5.0 28.7 ± 4.6 28.7 ± 4.5 30.9 ± 5.6 30.9 ± 5.7 29.9 ± 5.0 29.8 ± 4.8
25–29.9 kg/m2 (%) n.a. n.a. n.a. n.a. n.a. n.a. 43.7 42.6
≥30 kg/m2 (%) n.a. n.a. n.a. n.a. n.a. n.a. 42.4 43.2
Waist-Hip-ratio
Men n.a. n.a. n.a. n.a. 0.96 ± 0.07 0.96 ± 0.07 0.99 ± 0.08 0.98 ± 0.07
Women n.a. n.a. n.a. n.a. 0.86 ± 0.08 0.87 ± 0.08 0.90 ± 0.09 0.90 ± 0.08
History of 
Hypertension (%)
92.7* 92.0* 81* 81* 34.4 43.5 56.8 59.8
Heart rate (bpm) n.a. n.a. n.a. n.a. n.a. n.a. 74.0 ± 9.4 73.0 ± 9.8
Office systolic/
diastolic BP (mmHg)
154.5 ± 19.0/
87.4 ± 10.9
154.8 ± 19.0/
87.6 ± 10.7
164.1 ± 18.1/
94.8 ± 10.4
163.9 ± 18.0/
94.5 ± 10.4
136.1 ± 18.6/
83.4 ± 10.8
136.0 ± 18.1/
83.4 ± 10.8
147.4 ± 15.9/
87.3 ± 9.3
144.6 ± 15.3/
86.5 ± 9.4
HbA1c (mean %) n.a. n.a. n.a. n.a. n.a. n.a. 5.6 ± 0.6 5.6 ± 0.7
Risk factors
Smoker (%) n.a. n.a. 33 32 44.1 45.0 15.6 13.6
Dyslipidemia (%) n.a. n.a. n.a. n.a. 35.6 35.4 56.4 56.6
Hyperuricemia (%) n.a. n.a. n.a. n.a. n.a. n.a. 21.7 23.0
MAU (%) n.a. n.a. n.a. n.a. n.a. n.a. 6.2 5.4
CHD (%) 45.6 46.0 n.a. n.a. exclusion 13.9 14.2
Stroke/TIA (%) 19.8 19.8 n.a. n.a. exclusion exclusion
Drug therapy
Aspirin or antiplatelet 
agents (%)
n.a. n.a. 19 19 14.3 14.3 27.7 21.9
Thiazide diuretics (%) 35.9 35.1 n.a. n.a. 9.5 10.0 0.4 0
Nonthiazide diuretics 
(%)
n.a. n.a. 5.9 5.6 0 0
ACEi 41.3 41.4 n.a. n.a. 0 0.6
ARBs (%) 10.7 10.6 n.a. n.a. 5.6 5.3 0.9 1.2
Betablockers (%) 32.7 33.7 n.a. n.a. 17.2 17.5 0.3 0
CCBs (%) 41.7 40.2 n.a. n.a. 12.8 12.9 18.6 15.3
Alphablockers (%) 7.1 6.5 n.a. n.a. 1.9 2.2 2.1 2.0
Statins (%) n.a. n.a. 11** 10** 12.4 13.5 19.4 17.4
Fibrates (%) n.a. n.a. 2.1 2.3 0.1 0
* previously treated for hypertension; n.a. = not available; BMI = body mass index; MAU = microalbuminuria; CHD = coronary heart disease; TIA = 
transitory ischemic attack; ACEi = ACE inhibitors; ARBs = Angiotensin receptor blockers; CCBs = calcium channel blockers
** statins and fibrates combined.Cardiovascular Diabetology 2008, 7:22 http://www.cardiab.com/content/7/1/22
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cumference > 88 cm in women and 102 cm in men) was
associated with high sensitivity of IGT (i.e. identification
of individuals with pre-diabetes: 79%) as well as high spe-
cificity (i.e. exclusion of individuals without pre-diabetes:
74%) [22]. The low acceptance of the OGTT and the non
satisfying sensitivity and/or specificity of the sole HbA1c
determination speak against these parameters as inclusion
criteria for studies in daily practice. In contrast, the satis-
factory predictive value of the clinically easy to determine
dataset evaluated in PreDiSc was the rationale to use this
score as screening procedure in a prospective study.
Hypertensive patients fulfilling the PreDiSc criteria have a
very high likelihood to progress to overt diabetes. Com-
pared to the original PreDiSc score, on the basis of practi-
cal experiences in the initiation phase of the study two
amendments to the ADaPT protocol became necessary:
first, HbA1c was to be measured in a central laboratory
instead of the originally foreseen local laboratories (due
to wide variation in locally determined values). Second,
the age criterion was reduced to 45 years or older in order
to accelerate the inclusion rate.
Strength and limitations
Certain limitations of the investigation have to be taken
into account: first, it is controlled, but not randomised.
This means that the comparability of both cohorts can be
assessed retrospectively in terms of known factors that
may influence the outcomes (e.g. age, gender, comorbid-
ity), but not in terms of unknown bias. Second, the major-
ity of patients will require combination therapy of two,
three or even more antihypertensive drugs of various
classes. At clinical practice conditions, a substantial pro-
portion of patients may receive "unallowed" medications
in the course of the investigation (i.e., from the regimen
of the other arm). On the other hand, the real practice
conditions in this investigation convey substantial bene-
fits that will extend the knowledge from randomised stud-
ies. Patients will be less selected than typical study
patients. The dosing regimens and the combinations will
reflect current use (e.g. lower doses as compared to the US
for some drugs, inclusion of ARBs, etc.) and thus the
results can be easily extrapolated to day-to-day clinical
use.
Conclusion
Although there are some published RCTs on the develop-
ment of diabetes in patients on antihypertensive drugs,
the results are inconclusive and require further investiga-
tion. The ADaPT study will provide important clinical
data in a group of patients being at high risk to develop
diabetes for which clear guideline recommendations
regarding choice of antihypertensives are still missing.
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Valsartan Amlodipine Amlodipine Atenolol Ramipril Placebo ACEi Diuretic
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Hypertension 160–210/<115 mmHg ≥ 160/100 mmHg n.a. ≥ 140/90 mmHg
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